Alzheimer’s disease and early-stage dementia
Immungenetics AG focuses on clinical research in newly diagnosed early-to-mild dementia due to Alzheimer’s disease, with interest in the transition from mild cognitive impairment to early dementia.
- Early Alzheimer’s disease
- Mild cognitive impairment due to Alzheimer’s disease
- Neurodegenerative disease
The sponsor’s trial activity centers on disease-related changes in the brain linked to amyloid-beta clearance and clinical assessment in the early symptomatic stages of Alzheimer’s disease.
Neuroimaging and brain biomarker interest
The funded research includes diagnostic and therapeutic evaluation in Alzheimer’s disease, with attention to measures that reflect amyloid clearance and brain pathology in early disease.
- Aβ clearance
- Diagnostic assessment
- Biomarker-linked disease monitoring
This area reflects an interest in linking treatment effects with biological markers relevant to early neurodegeneration.
Therapeutic evaluation in cognitive decline
Clinical research activity includes the assessment of thiethylperazine as a potential therapeutic agent in patients with early cognitive symptoms associated with Alzheimer’s disease.
- Symptomatic cognitive impairment
- Early dementia treatment
- Drug repurposing in neurology
The sponsor’s therapeutic interest is concentrated on interventions intended for the early clinical course of Alzheimer-related cognitive deterioration.
Clinical development in neurology
Immungenetics AG’s research portfolio is centered on a single neurology-focused program conducted across multiple collaborating sites in Germany.
- Multisite clinical research
- Alzheimer-focused development
- Early intervention strategies
The sponsor’s activity is directed toward clinical questions in the management of early-stage neurocognitive disorders.
